Table 1.
Endpoint code | Endpoint | Endpoint description | Training set | Validation set | ||
---|---|---|---|---|---|---|
#Sample | P/N ratio* | #Sample | P/N ratio | |||
A | Lung tumorigenicity | Lung tumorigen vs. non-tumorigen | 70 | 0.59 | 88 | 0.47 |
B | Non-genotoxicity | Non-genotoxic hepatocarcinogen vs. non-carcinogen | 216 | 0.51 | 201 | 0.4 |
C | Liver toxicity | Liver toxicants vs. non-toxicants | 214 | 0.58 | 204 | 0.62 |
D | Breast cancer | Pathologic complete response, pCR | 130 | 0.34 | 100 | 0.18 |
E | Breast cancer | Estrogen receptor status (ER +/-) | 130 | 1.6 | 100 | 1.56 |
F | Multiple myeloma | Overall survival | 340 | 0.18 | 214 | 0.14 |
G | Multiple myeloma | Event-free survival | 340 | 0.33 | 214 | 0.19 |
H | Multiple myeloma | Male vs. female (positive control) | 340 | 1.33 | 214 | 1.89 |
I | Multiple myeloma | Random 2-class label (negative control) | 340 | 1.43 | 214 | 1.33 |
J | Neuroblastoma | Overall survival | 238 | 0.1 | 177 | 0.28 |
K | Neuroblastoma | Event-free survival | 239 | 0.26 | 193 | 0.75 |
L | Neuroblastoma | Male vs. female (positive control) | 246 | 1.44 | 231 | 1.36 |
M | Neuroblastoma | Random 2-class label (negative control) | 246 | 1.44 | 253 | 1.36 |
* P/N = Positive/Negative ratio. Positive denotes for these samples showing the positive results (e.g. cancer, tumor).